N/A N=24 Intervention to Change Attributions That Are Negative (ICAN)
Trauma, Brain · Brain Injuries · Traumatic Brain Injury
Primary: Change in Buss-Perry Aggression Questionnaire Score — -1.7; -5.91; -8.51 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=233 Asthma Symptom Management Through Mindfulness Training
Asthma
Primary: Change From Baseline in Asthma Control at 18 Months — 1.27; 1.17 score on a scale
Phase 1 N=49 Safety Study of Tezepelumab (AMG 157) in Healthy Adults
Healthy Volunteers
Primary: Number of Participants With Treatment-emergent Adverse Events — 4; 4; 2; 6 Participants
Phase 2 N=17 Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia
Plasma Cell Leukemia · Plasma Cell Myeloma · Plasmacytoma
Primary: Confirmed Response Rate — 0.06 proportion of patients
Phase 1 N=22 Evaluating Relative Bioavailability of OC-01 (Varenicline) Nasal Spray as Compared to Orally Administered Varenicline
Healthy Subjects
Primary: AUC0-t — 4.49; 98.74 h*ng/ml
Phase 2 N=23 NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
Lymphoblastic Lymphoma
Primary: Probability of Event-free Survival (EFS) — 91.7; 71.4; 100; 86.96 percentage of event-free patients
Phase 1 N=20 Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults
HIV Infections
Primary: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Time t (AUC[0-t]) for Caffeine — 37970; 42230 Hour*nanograms per milliliter (h*ng/mL)
Phase 4 N=15 Pharmacokinetics of Single-Dose Liposomal Bupivacaine in Surgeon Performed Intercostal Nerve Blocks
Thoracic
Primary: Tmax, or the Time Until the Maximum Concentration — 24 Hours
Phase 2 N=365 A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder
Insomnia Disorders
Primary: Change From Baseline in Latency to Persistent Sleep (LPS) as Measured by Polysomnography (PSG) on Night 1 — -15.24; -29.92; -49.49; -47.69 Minutes — p== 0.346
Phase 3 N=126 Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Primary: Overall Response Rate (ORR) — 84.4; 69.4 percentage of participants — p=0.0463
Phase 3 N=100 Exparel Use in Adductor Canal Block After Total Knee Arthroplasty
Arthritis Knee · Pain, Postoperative · Opioid Use
Primary: Hospital Length of Stay — 36.3; 49.7 Hours — p=<0.05
N/A N=50 A Cognitive Behavioral Therapy (CBT) Intervention to Reduce Fear of Hypoglycemia in Type 1 Diabetes
Type 1 Diabetes Mellitus
Primary: Fear of Hypoglycemia — 54.3; 58.7; 35.29; 49.0 units on a scale
N/A N=539 Online Trial Examining Validity and Reliability of the Shared Decision Making Process Survey
High Cholesterol · High Blood Pressure · Colorectal Cancer
Primary: Shared Decision Making Process Measure — 2.12; 2.65; 1.61; 1.4 score on a scale
Phase 2 N=8 Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Progression-free Survival at 18 Months (PFS18) Defined as the Proportion of Patients Alive and Free From Disease Progression at 18 Months From Study Entry — 0.3750…
N/A N=23 MBSR During AI Therapy for Breast Cancer
Breast Cancer · Cognitive Symptom
Primary: Functional Neural Activation Parameter Estimate — -1.2; -1.8; -0.8; -0.7 beta weights — p=0.460